Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development

Dorothy I. Shulman, Gary L. Francis, Mark R. Palmert, Erica A. Eugster

Research output: Contribution to journalReview article

50 Scopus citations


Although treatment of children and adolescents who have disorders of growth and adolescent development with aromatase inhibitors is increasingly common, data for or against their use are extremely limited. Precocious puberty, short stature, and gynecomastia are conditions for which inhibition of the enzyme aromatase might prove beneficial to reduce clinical signs of estrogenization and/or estrogen-mediated skeletal maturation. In this report, we summarize the published data regarding the use of aromatase inhibitors in these conditions, and review known and potential benefits, safety concerns, and shortcomings of the available information.

Original languageEnglish (US)
Pages (from-to)e975-e983
Issue number4
StatePublished - Apr 1 2008



  • Aromatase inhibitors
  • Gynecomastia
  • Precocious puberty
  • Short stature

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this